Chemed Corp
NYSE:CHE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
525.03
650.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Chemed Corp
Chemed Corp
Net Issuance of Common Stock
Chemed Corp
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chemed Corp
NYSE:CHE
|
Net Issuance of Common Stock
-$98.2m
|
CAGR 3-Years
33%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
Net Issuance of Common Stock
-$1.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Net Issuance of Common Stock
-$211m
|
CAGR 3-Years
53%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-22%
|
|
|
CVS Health Corp
NYSE:CVS
|
Net Issuance of Common Stock
-$2.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Cigna Corp
NYSE:CI
|
Net Issuance of Common Stock
-$5.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-15%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Net Issuance of Common Stock
-$113m
|
CAGR 3-Years
43%
|
CAGR 5-Years
31%
|
CAGR 10-Years
11%
|
|
Chemed Corp
Glance View
Chemed Corp. is a distinguished player in the healthcare sector, known primarily for its two main subsidiaries: VITAS Healthcare and Chemed Home Health. VITAS is the nation’s leading provider of hospice and palliative care services, which cater to patients with life-limiting illnesses. This segment underscores Chemed’s dedication to enhancing the quality of life for patients and their families, focusing on compassionate care and support during critical times. Operating in a market increasingly underpinned by an aging population and a growing preference for home-based healthcare solutions, Chemed stands to benefit from favorable demographic trends. In addition, its Chemed Home Health division positions the company well within the rapidly expanding home healthcare market, facilitating personalized care in a familiar environment, which has shown significant promise in improving patient outcomes. For investors, Chemed Corp. offers a compelling investment narrative characterized by steady growth, financial stability, and a robust operational model. The company has demonstrated strong revenue generation and consistently high margins, reflective of its effective management and operational efficiencies. With a solid balance sheet and commitment to shareholder returns, Chemed has a track record of delivering value through dividends and strategic reinvestments. Moreover, as healthcare policies increasingly favor in-home care solutions and as demographics shift towards an older population, Chemed is poised to capture considerable market opportunities. Its proven ability to adapt to changing healthcare needs not only underlines its resilience but also highlights its potential for sustained financial performance and long-term growth.
See Also
What is Chemed Corp's Net Issuance of Common Stock?
Net Issuance of Common Stock
-98.2m
USD
Based on the financial report for Sep 30, 2024, Chemed Corp's Net Issuance of Common Stock amounts to -98.2m USD.
What is Chemed Corp's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-5%
The average annual Net Issuance of Common Stock growth rates for Chemed Corp have been 33% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
